Fukuoka Cancer Comprehensive Clinic: Advanced Apheresis and Cell Therapy

Fukuoka Cancer Comprehensive Clinic represents a strategic partnership with Medical Supporter. Under the leadership of Dr. Takashi Morisaki, leveraging extensive clinical research experience at Kyushu University Hospital, the clinic specializes in immune cell therapy applications for advanced cancer adjuvant treatment.

Two Core Technology Platforms

Advanced Apheresis Technology: Unlike standard whole blood collection, the clinic employs precision component apheresis systems. Immune cells (T cells, NK cells) are selectively extracted via blood separator technology, with plasma and red cells immediately returned to the patient.

Advantage: Sufficient cellular material obtained in single procedure, dramatically reducing phlebotomy burden in weakened patients.

In-House CPC Laboratory: To prevent cell damage during transport, the clinic maintains Ministry of Labor-certified Cell Processing Center (CPC) on-site.

Quality Assurance: Culture initiation within minutes of apheresis ensures maximum cell viability and cytotoxic potency upon reinfusion.

Treatment Modalities

Activated Lymphocyte Therapy: Synchronized T cell and NK cell expansion

Dendritic Cell Vaccine (DC): Tumor-specific antigen presentation strategy

Peptide Vaccine Combinations: Personalized HLA-matched peptide therapy

Data Source

Fukuoka Cancer Comprehensive Clinic Clinical Program

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).